[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors—Reply

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

In Reply: Dr Burnakis points out that COX-2 inhibitors decrease GI complications by 1% to 2% while increasing CV events by approximately 0.3%, and suggests that this is a fair trade. We do not want to downplay the morbidity associated with serious GI complications but would like to point out that clinical trials have evaluated COX-2 inhibitors in mostly healthy patients without CV diseases. The low cardiovascular risk of the population studied and the short follow-up in the trials to date may significantly underestimate the CV hazard.

First Page Preview View Large
First page PDF preview
First page PDF preview